Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMICUS THERAPEUTICS, INC. Director's Dealing 2018

Jan 25, 2018

31523_dirs_2018-01-25_2851096b-1f36-478e-89ad-b75012ac905e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2018-01-23

Reporting Person: Barth Jay (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-01-23 Common Stock M 20000 $2.29 Acquired 105409 Direct
2018-01-23 Common Stock S 20000 $16.80 Disposed 85409 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-01-23 Stock Options (right to buy) $2.29 M 20000 Disposed 2024-03-03 Common Stock (20000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 125 Indirect

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017.

F2: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vested on March 3, 2015. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on April 1, 2015, with the final installment vesting on March 1, 2018.